



COPY OF PAPERS  
ORIGINALLY FILED

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

In Re Application of:

Chudzik et al.

Serial No. 09/901,425

Filed: 9 July 2001

For: MEDICAMENT INCORPORATION  
MATRIX

To: Commissioner for Patents  
Washington, D.C. 20231

) Art Unit: 1615

)

) Our Ref. 9896.139.3

)

)

)

)

)

)

)

)

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

☐ facsimile transmitted to the Patent and Trademark Office

☐ hand delivered to the Patent and Trademark Office

on this 10 day of April 2002

By Moddy E. Thompson

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure, a completed Form PTO-1449 is enclosed.

Consideration of the listed reference by the Examiner is respectfully requested. Applicant also respectfully requests that an initialed copy of Form PTO-1449 indicating such consideration be returned with the next Official Action, as set forth in MPEP 609. Attached hereto are copies of the following references. Also enclosed is a copy of PCT Search Report Form PCT/ISA/220 listing these references.

International Publication No. WO 99/47176 (Surmodics, Inc.)

International Publication No. WO 99/47129 (Surmodics, Inc.)

International Publication No. WO 01/21326 (Surmodics, Inc.)

Peppas N.A., et al., "Poly(ethylene Glycol)-Containing Hydrogels in Drug Delivery", *Journal of Controlled Release, Elsevier Science Publishers B.V.*, Amsterdam, NL, Vol. 62, No. 1/2, (1999), pages 81-87.


By submitting these references, Applicant does not admit that the references are prior art to or material to this application, and reserves the right to establish that any reference is not prior art. Applicant does not represent that the references have been reviewed in detail; there may be details in the references of which Applicant is unaware.

The Commissioner is hereby authorized to charge any additional filing fees required to Deposit Account No. 061910. A duplicate copy of this sheet is enclosed.

Dated: \_\_\_\_\_

*9 APR 2002*

Respectfully submitted,



Philip M. Goldman  
Registration No. 31,162  
Fredrikson & Byron, P.A.  
1100 International Centre  
900 Second Ave. South  
Minneapolis, MN 55402-3397  
(612) 347-7088  
Customer No. 022859

PMG/Supp.IDS  
09/901,425  
2631393



COPY OF PAPERS  
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of:

Chudzik et al.

Serial No. 09/901,425

Filed: 9 July 2001

For: MEDICAMENT INCORPORATION  
MATRIX

To: Assistant Commissioner for Patents  
Washington, D.C. 20231

) Art Unit: 1615

)

) Our Ref. 9896.139.3

)

)

)

)

)

)

)

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

☐ facsimile transmitted to the Patent and Trademark Office

☐ hand delivered to the Patent and Trademark Office

on this 10 day of April, 2002

By Modily E. Thornyn

CERTIFICATION UNDER 37 CFR §1.97(e)(2)

This certification is being made for the Information Disclosure Statement accompanying this certification. I, Philip M. Goldman, hereby certify that each item of information contained in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Dated: 9 APR 2002

Respectfully submitted,

Philip M. Goldman  
Philip M. Goldman  
Registration No. 31,162  
Fredrikson & Byron, P.A.  
1100 International Centre  
900 Second Avenue South  
Minneapolis, MN 55402-3397  
(612) 347-7088  
Customer No. 022859

[illegible]